Approaching DEADLINE: Traders With Substantial Losses Have Chance to Lead the Frequency Therapeutics, Inc. Class Motion Lawsuit

San Diego, California–(Newsfile Corp. – July 26, 2021) – The Frequency Therapeutics, Inc. (NASDAQ: FREQ) class motion lawsuit rates Frequency Therapeutics and its CEO with violations of the Securities Trade Act of 1934 and seeks to characterize purchasers of Frequency Therapeutics common inventory concerning November 16, 2020 and March 22, 2021, inclusive (the “Class Interval”). The Frequency Therapeutics class motion lawsuit (Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933) was commenced on June 3, 2021 in the District of Massachusetts and is assigned to Decide William G. Younger. A comparable lawsuit (Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040) is also pending in the District of Massachusetts.

If you suffered considerable losses and desire to serve as lead plaintiff of the Frequency Therapeutics class action lawsuit, make sure you present your details by clicking right here. You can also speak to legal professional J.C. Sanchez of Robbins Geller by contacting 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Frequency Therapeutics class motion lawsuit should be submitted with the court no later on than August 2, 2021.

Case ALLEGATIONS: The Frequency Therapeutics course action lawsuit alleges that, shortly immediately after launching the Period Forex-322 2a trial, Frequency Therapeutics and its Chief Govt Officer, defendant David L. Lucchino, figured out that the Period 2a demo outcomes exposed no discernable change between Fx-322 and the placebo. The Frequency Therapeutics class motion lawsuit even further alleges that, when Frequency Therapeutics’ inventory value remained artificially inflated, defendant Lucchino offered in excess of 350,000 Frequency Therapeutics shares, pocketing above $10.5 million.

On March 23, 2021, Frequency Therapeutics disclosed deeply disappointing interim Section 2a results, revealing that subjects with delicate to reasonable extreme sensorineural listening to loss did not exhibit advancements in listening to actions versus placebo. On this information, Frequency Therapeutics’ stock rate fell by practically 78%, detrimental traders.

THE Lead PLAINTIFF Procedure: The Non-public Securities Litigation Reform Act of 1995 permits any investor who obtained Frequency Therapeutics frequent inventory during the Class Period to look for appointment as lead plaintiff in the Frequency Therapeutics course motion lawsuit. A guide plaintiff is usually the movant with the greatest monetary desire in the reduction sought by the putative class who is also usual and suitable of the putative course. A lead plaintiff acts on behalf of all other course users in directing the Frequency Therapeutics class action lawsuit. The lead plaintiff can choose a law business of its alternative to litigate the Frequency Therapeutics class action lawsuit. An investor’s skill to share in any opportunity long run restoration of the Frequency Therapeutics class motion lawsuit is not dependent upon serving as direct plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 places of work nationwide, Robbins Geller Rudman & Dowd LLP is the most significant U.S. regulation company symbolizing traders in securities course actions. Robbins Geller lawyers have attained quite a few of the premier shareholder recoveries in background, including the major securities class motion recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Motion Services Top rated 50 Report ranked Robbins Geller initial for recovering $1.6 billion for investors very last calendar year, much more than double the sum recovered by any other securities plaintiffs’ agency. You should pay a visit to https://www.rgrdlaw.com/firm.html for more info.

Legal professional marketing.

Past final results do not assure upcoming results.

Services may perhaps be carried out by attorneys in any of our offices.

Make contact with:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]

To perspective the supply variation of this push launch, please visit https://www.newsfilecorp.com/release/91126